• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Retinal pigment epithelium rip with posterior uveitis after intravitreal brolucizumab in neovascular age-related macular degeneration.

作者信息

Dabir Supriya, Mohankumar Arthi, Rao Vaishnavi Prasad, Rajan Mohan

机构信息

Department of Retina and Vitreous, Rajan Eye Care Hospital Pvt Ltd., 5, Vidyodaya Second Street, T. Nagar, Chennai, Tamil Nadu, India.

出版信息

Indian J Ophthalmol. 2024 Feb 1;72(2):292-294. doi: 10.4103/IJO.IJO_712_23. Epub 2024 Jan 25.

DOI:10.4103/IJO.IJO_712_23
PMID:38273689
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10941935/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba66/10941935/237ad55a8b95/IJO-72-292b-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba66/10941935/1fd6d23b1475/IJO-72-292b-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba66/10941935/237ad55a8b95/IJO-72-292b-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba66/10941935/1fd6d23b1475/IJO-72-292b-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba66/10941935/237ad55a8b95/IJO-72-292b-g002.jpg

相似文献

1
Retinal pigment epithelium rip with posterior uveitis after intravitreal brolucizumab in neovascular age-related macular degeneration.玻璃体内注射布罗珠单抗治疗新生血管性年龄相关性黄斑变性后出现视网膜色素上皮撕裂并伴后葡萄膜炎
Indian J Ophthalmol. 2024 Feb 1;72(2):292-294. doi: 10.4103/IJO.IJO_712_23. Epub 2024 Jan 25.
2
Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.玻璃体内注射布罗利珠单抗转换治疗新生血管性年龄相关性黄斑变性的真实临床经验和预测结果。
Ophthalmologica. 2023;246(2):158-168. doi: 10.1159/000530544. Epub 2023 Apr 11.
3
Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.Brolucizumab 治疗伴有色素上皮脱离的年龄相关性黄斑变性的难治性黄斑新生血管
Eur J Ophthalmol. 2024 Mar;34(2):487-496. doi: 10.1177/11206721231187663. Epub 2023 Jul 18.
4
Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration.玻璃体内注射布罗利珠单抗治疗渗出性年龄相关性黄斑变性后对未注射侧眼的影响。
Eur J Ophthalmol. 2024 Jan;34(1):NP104-NP107. doi: 10.1177/11206721231187429. Epub 2023 Jul 9.
5
Retinal pigment epithelium apertures associated with subretinal fluid and acquired vitellifom lesions in non-neovascular age-related macular degeneration.视网膜色素上皮裂孔与非新生血管性年龄相关性黄斑变性中的视网膜下液及获得性卵黄样病变相关。
Can J Ophthalmol. 2022 Jun;57(3):e91-e94. doi: 10.1016/j.jcjo.2021.09.013. Epub 2021 Nov 3.
6
[Bilateral occlusive vasculitis after intravitreal injection of brolucizumab in neovascular age-related macular degeneration].[玻璃体内注射布罗芦izumab治疗新生血管性年龄相关性黄斑变性后双侧闭塞性血管炎]
Ophthalmologe. 2022 Jan;119(1):75-78. doi: 10.1007/s00347-021-01323-6. Epub 2021 Feb 11.
7
Full thickness macular hole after intravitreal brolucizumab injection in neovascular age-related macular degeneration.在新生血管性年龄相关性黄斑变性患者玻璃体内注射布罗珠单抗后出现的全层黄斑裂孔。
Eur J Ophthalmol. 2025 Jan;35(1):NP16-NP19. doi: 10.1177/11206721241286708. Epub 2024 Sep 27.
8
Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER.布罗利珠单抗和阿柏西普对HAWK和HARRIER研究中色素上皮脱离及视网膜下色素上皮液最大厚度的影响。
Ophthalmol Retina. 2025 Jan;9(1):13-21. doi: 10.1016/j.oret.2024.07.012. Epub 2024 Jul 19.
9
[Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration].[布罗芦izumab治疗顽固性新生血管性年龄相关性黄斑变性的真实生活经验]
Ophthalmologe. 2022 Mar;119(3):258-264. doi: 10.1007/s00347-021-01474-6. Epub 2021 Aug 5.
10
Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.布罗利珠单抗和法西单抗在新生血管性年龄相关性黄斑变性中的功能和形态学变化比较。
Graefes Arch Clin Exp Ophthalmol. 2024 Feb;262(2):589-599. doi: 10.1007/s00417-023-06241-8. Epub 2023 Sep 26.

本文引用的文献

1
Three cases of brolucizumab-associated retinal vasculitis treated with systemic and local steroid therapy.三例与布罗鲁单抗相关的视网膜血管炎经全身和局部类固醇治疗。
Jpn J Ophthalmol. 2021 Mar;65(2):199-207. doi: 10.1007/s10384-021-00818-8. Epub 2021 Feb 5.
2
Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study.布罗鲁单抗相关的视网膜血管炎伴雷珠单抗再次治疗后病情加重：一项临床病理病例研究。
Am J Ophthalmol Case Rep. 2020 Nov 10;20:100989. doi: 10.1016/j.ajoc.2020.100989. eCollection 2020 Dec.
3
Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations.
多次玻璃体内注射布罗珠单抗后继发视网膜小动脉阻塞导致严重视力丧失。
Am J Ophthalmol Case Rep. 2020 Apr 2;18:100687. doi: 10.1016/j.ajoc.2020.100687. eCollection 2020 Jun.
4
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.HAWK 和 HARRIER：贝鲁珠单抗治疗新生血管性年龄相关性黄斑变性的 3 期、多中心、随机、双盲试验。
Ophthalmology. 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017. Epub 2019 Apr 12.
5
Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study.单链抗体片段 VEGF 抑制剂 RTH258 治疗新生血管性年龄相关性黄斑变性：一项随机对照研究。
Ophthalmology. 2016 May;123(5):1080-9. doi: 10.1016/j.ophtha.2015.12.030. Epub 2016 Feb 20.